Imuna Pharm in trouble
Imuna Pharm, infusion solutions and blood derivatives maker owned by Juraj Kamarás and Ladislav Krajňák, is facing financial woes, and its owners must find fresh capital. It has obtained €7.2m in EU funds since 2014, but has suffered €3.2m losses since 2015, owes €0.2m in payroll levies, and its bank withdrew a credit line. Its sales stagnated at €18.1m last year, and the pandemic reduced demand as hospitals postponed many surgeries. It is continuing on with an €8m investment into capacity extension, and has completed another €15m investment into technologies in 2016. It still employs 200.
Krajňák and Kamarás were forced to reduce their workforce in Valcovňa profilov, a metal sheet processor, by 40 to 120 due to a slump in demand.